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Abstract    
Background 
Successful hepatitis C virus (HCV) therapy depends on effective pathways of care. Over 2 decades we 
have developed 4 sequential models of care latterly using a multi-disciplinary managed care network 
(MCN) to improve HCV testing, care and treatment. 
Methods 
Cohort study to evaluate the effectiveness of care pathways, carried out using all HCV antibody positive 
individuals tested in a geographical region between 1994 and 2014. 
Results 
Study of 3122 HCV positive patients. They were divided into four subgroups representing different care 
pathways defined by their date of HCV antibody diagnosis. The number who accessed treatment 
services within 1 year of diagnosis increased from 77/292 (26.3%) to 521/821 (72.9%).  The rate of 
treatment starts within 1 year of diagnosis increased from 6/292 (2.0%) to 133/821 (16.2%), and the 
sustained viral response rate improved from 61.6% to 77.4%.  All-cause mortality decreased from 
232/688 (33.7%) in subgroup A to 55/1207 (4.5%) in subgroup D, multivariate analysis showed that 
pathway type was an independent predictor of mortality irrespective of age, sex, SVR status or HIV co-
infection with pathway D having an odds ratio of 0.53(0.40-0.77 p<0.001) compared to pathway in A.  At 
study end 78% (3122) of estimated 4000 HCV positive had been diagnosed. 97.5% of HCV caseload 
was referred to Specialist Services and 89% attended for assessment. 
Conclusions 
The introduction of a MCN increases access to care and reduced all cause mortality.   
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Introduction 
Hepatitis C virus infection is a major public health problem, chronic infection occurs in 75 to 80% of 
cases and in the long term there is a considerable risk of liver cirrhosis and liver cancer (1). It is 
estimated that there are between 130 to 150 million people infected globally which results in 350,000 to 
500 000 deaths a year (2). With the advent of highly effective direct acting antiviral oral therapies it is 
possible to successfully treat and cure virtually everyone with hepatitis C. However achieving cure 
requires not just the availability of efficacious treatment but the effective delivery of that treatment to 
those in need. The key to reducing the burden of liver disease from HCV for a region, is the diagnosis 
and delivery of treatment, to all patients who need it. This requires taking responsibility for a defined 
region and all the HCV infection within that region, irrespective of how and by whom the virus was 
contracted. 
 
Recent estimates suggest that around 215,000 are chronically infected with hepatitis C in the UK and it 
is estimated that over 90% of cases are related to injecting drug use. (3).The majority who are referred to 
the specialist hepatitis services will be past or present drug users. People who inject drugs (PWIDs) are 
thought to be a particularly difficult population to reach as they may have difficulty accessing and using 
traditional medical services.   
 
Expert consensus suggests that increasing testing and uptake of services may be improved not just by 
the integration of diagnosis and treatment but also by integrated multidisciplinary care which also 
addresses the individuals’ alcohol, drug use problems, social circumstances and general health 
simultaneously with their HCV specialist care (4-9). These concepts of care have not been rigorously 
tested in clinical trials, as they are systems changes that cannot be randomised to individuals. 
 
The Tayside region of Scotland has been a test bed for sequential development of integrated services 
over the last 2 decades; moving from standard secondary care based hospital outpatients, onto nurse 
supported treatment services, then to a HCV Managed Care Network (MCN) (10,11), and finally to a 
development in the MCN model which included a widespread dry blood spot testing programme in drug 
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services and development in our outreach services across the region which included providing treatment 
within drug services and prisons (12).  
 
The aims of the study were to evaluate the outcomes of the individuals who had a positive hepatitis C 
antibody test in our region and to compare referral patterns, attendance and treatment outcomes over 
those 4 developmental stages, to investigate if these changes translated into better clinical outcomes. 
 
Methodology 
This is a cohort study of all adults who have received a positive hepatitis C antibody test in the 
geographical region of Tayside, Scotland. The region has two cities, several major towns, a mixed urban 
and rural population with significant areas of deprivation and associated drug use. This is representative 
in microcosm of most developed health regions. This is an all-inclusive population based study of the 
performance of a health care system for the diagnosis and treatment of HCV. All HCV positive 
individuals have been included in our clinical database which was established in 2004. Retrospective 
data was collected on those tested before 2004 and prospective data was entered into the database for 
everyone who tested positive after 2004. Data collected included demographic information, risk factors, 
laboratory tests, referral details, follow up and treatment outcomes. The study period for new patient 
entry closed at the end of June 2014, with at least one year follow after a HCV positive test for all 
patients until end June 2015. Patients were followed up in or out of service from first diagnosis until SVR, 
death or moving residence outside the region. 
 
Individuals were divided into 4 sub groups. These sub groups were based on the specialist pathway 
available at the time of their first postive antibody test . It is important to note that patients were analysed 
according to the date of first antibody test and may have entered or been in care through multiple care 
pathway development periods and the care they experienced would have changed as the whole service 
was developed. 
 
Group Time period  Interventions 
Subgroup A Pre July1999  HCV testing commenced in region 
 Limited access to treatment 
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 No specialist nursing input available  
Subgroup B July 1999- 
June 2004 
 Specialist nursing support given at HCV treatment clinic  
 Clinic at main city hospital only  
 Treatment offered, interferon and ribavirin 
Subgroup C July 2004-
June 2009 
 Development of managed care network  
 Appointment  of part time Nurse specialist  
 New referral pathway- referrals open to all health care 
professionals including drug workers and prison nurses 
 Outreach clinics established locally and in drug and prison 
centres centres throughout region 
 Treatment interferon and ribavirin  
Subgroup D July 2009-
June 2014 
 Routine dry blood spot testing in drug services and needle 
exchanges 
 Appointment of full time nurse specialist 
 Increase in outreach clinics across region 
 Treatment use of Direct Acting Antivirals (DAAs) in treatment 
regimen 
 
Results  
 
Phase 1 analysis: all HCV antibody positive analysis 
 
There were 3122 new positive HCV antibody results during the period of the study. The first recorded 
test was the 2nd of April 1984 (performed retrospectively on stored serum) and the last test was the 28th 
of June 2014. Eight HCV antibody positive individuals who had tested positive in other regions and 
moved into our service while on treatment were excluded. 
 
The first stage in the HCV care pathway is testing and diagnosis. The type and location of healthcare 
worker who carried out the first positive HCV test was documented. In subgroups A, B and C in 40% of 
cases this was the General Practitioner. The number tested by drug workers increased significantly from 
4.5% in subgroup A to 35.8% within subgroup D when dry blood spot testing was introduced to drug 
services. (Table 1) By the end of the study 78% (3122) of our estimated 4000 HCV antibody positive 
people in our area had been diagnosed. 
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Across the cohort the mean age was 35.7 years and 73.9% were male. 118 (3.7%) were co-infected with 
HIV and 10 (0.3%) were hepatitis B surface antigen positive. Thirty-four acute episodes of hepatitis C 
were diagnosed, the majority (27) were diagnosed in the last subgroup (subgroup D) when yearly dry 
blood spot testing was routinely available in Drug Services. The risk factor(s) was documented in 97.2% 
of cases. In 85 cases there was no documentation on the request form and the individual’s risks was not 
identifiable because they had died, were unable to be traced or were no longer resident in the area. The 
majority of individuals (81.7%) had a history of injecting drug use and 191 (6.2%) did not disclose any 
known risk factors.  Table 1 lists further data for each subgroup. 
 
The first phase of analysis was based on all antibody positive individuals in each of the four subgroups; 
endpoints in this phase of the analysis were spontaneously resolving infection (651), dying before 
accessing care (324), moving from the region before accessing care (294) or unable to be traced (23). 
The high number moving out of the region before accessing care is a reflection of the three prisons in the 
area. They were not followed up from the point they moved out with the region. In addition there were a 
number of individuals who had died before accessing care; this number was particularly high in the first 
two subgroups.  
 
Table 1: Outcome of new diagnosis of HCV 
 Subgroup A 
(n=688) 
Subgroup B 
(n=634) 
Subgroup C 
(n=593) 
Subgroup D 
(n=1207) 
Tester General Practitioner  227 (32.9%) 265 (41.7%) 222 (37.4%) 276 (22.8%) 
 Prison Services 150 (21.8%) 131 (20.6%) 118 (19.8%) 174 (14.4%) 
 Hospital inpatient/outpatient 111 (16.1%) 76 (11.9%) 85 (14.3%) 195 (16.1%) 
 Other 84 (12.2%) 98 (15.4%) 82 (13.8%) 120 (9.9%) 
 HIV Specialist Team 56 (8.1%) 24 (3.7%) 21 (3.5%) 9 (0.7%) 
 Drug services 31 (4.5%) 36 (5.6%) 64 (10.4%) 433 (35.8%) 
 Haematology 29 (4.2%) 4 (0.6%) 1 (0.1%) 0 (0%) 
Median age at diagnosis (Age range) 34.9 years 
 
35.5years 36.8 years 35.8years 
Male (%) 
 
531 (77.6%) 492 (77.3%) 428(72%) 831(68.6%) 
Ethnic group British Caucasian (%) 
 
674 (97.9%) 618 (97.4%) 551 (92.9%) 1116 (92.4%) 
Risk Factor Blood products 50 (7.2%) 18 (2.8%) 25 (4.2%) 21 (1.7%) 
Intravenous drug use 496 (72.0%) 501 (81.0%) 450 (75.8%) 103 (87.5%) 
From high prevalence country 14 (2.0%) 15 (2.3%) 38 (6.4%) 81 (5.0%) 
No risk factors known 55 (7.9%) 36 (5.6%) 38 (6.4%) 52 (4.3%) 
Other (sexual, tattoo, needle stick) 32 (4.6%) 35 (5.5%) 36 (6.1%) 42 (3.4%) 
Not documented 37 (5.4%) 29 (4.7%) 2 (0.3%) 2 (0.1) 
Co morbities HIV 59 (8.5%) 32 (5.0%) 20 (3.3%) 7 (0.5%) 
HBV 1 (0.1%) 3 (0.5%) 4 (0.7%) 2 (0.1%) 
Haemophilia 19 (2.8%) 0 (0%) 1 (0.1%) 0 (0%) 
 
HCV PCR 
Positive 339 (49.2%) 445 (70.1%) 469 (7.1%) 830 (68.7%) 
Negative 93 (13.5%) 135 (21.2%) 103 (17.3%) 320 (26.5%) 
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status Not known 256 (37.2%) 54 (8.5%) 21 (3.5%) 57 (4.7%) 
Acute infection diagnosed 
 
1 (0.1%) 3 (0.4%) 3 (0.5%) 27 (2.2%) 
Non Resident/moved 
 
103 (14.9%) 93 (14.6%) 58 (9.7%) 40 (3.3%) 
Death before access to care  181(26.3%) 82 (12.9%) 39 (6.5%) 22 (1.8%) 
No Trace 
 
19 (2.7%) 0 (0%) 0 (0%) 4 (0.3%) 
Total leaving study at phase 1 (1292) 396 310 200 386 
Total requiring specialist care (1830) 
 
292 324 393 821 
 
 
Phase 2 analysis: HCV PCR positive or unknown analysis 
 
The second phase of the study included 1830 individuals who were HCV PCR positive or HCV PCR 
status was unknown, who were living in our region (i.e. the target population for any treatment 
programme). The aim was to compare referral, attendance and treatment outcomes in each subgroup to 
determine if changes to practice had a significant impact on outcomes. This is presented as cumulative 
data, time periods from referral to access to care and treatment.  
 
Across the subgroups 1786 (97.5%) were referred to our Specialist Services with 1629 (89%) attending 
at least one clinic appointment for assessment. The data represents cumulative attendance in the table 
so sub groups A, B and C have had longer and more opportunities to engage with services than sub 
group D. Over the course of the study the number of individuals who accessed specialist care within a 
year of diagnosis significantly increased from 26.3% to 72.9% (Table 2). 
 
The mean age did not vary significantly in the sub groups, in the last 2 subgroups the proportion of 
females who attended increased as did the proportion of PWIDs who accessed care. The genotype 
distribution across the study changed through time. In subgroup A, 55.2% were genotype 1 and this 
decreased to 38.5% in subgroup D, consequently genotype 3 infection rates rose from 40.4% in 
subgroup A to 58.2% in sub group (Table 2). This probably reflects greater testing in active PWID in 
subgroup D. 
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Table 2: Final outcomes of HCV PCR positive individuals  
 
 Subgroup A Subgroup B Subgroup C 
 
Subgroup D 
Caseload total (1830) n= 292 n=324 n=393 n=821 
Total referred  (1786) 279 (95.5%) 320 (98.7%) 386 (98.2%) 801 (97.5%) 
Referrer  GP 121 (43.3%) 163 (50.9%) 172 (43.7%) 256 (31.3%) 
 Other Hospital 44 (15.7%) 43 (13.4%) 40 (10.1%) 82 (9.9%) 
 Prison service 39 (13.9%) 51 (15.9%) 71 (15.5%) 103 (12.8%) 
 Drug Services 21 (7.5%) 23 (7.1%) 70 (18.1%) 315 (39.3%) 
 Other  54 (19.3%) 40 (12.5%) 33 (8.5%) 45 (5.6%) 
Did not attend clinic   
 
32 19 31 139 
Accessed care (1629) 
 
260 (89%) 305 (94.1%) 362 (92.1%) 702 (85.5%) 
Accessed care within one year 
of positive test 
77 (26.3%) 76 (23.4%) 262 (66.6%) 599 (72.9%) 
Accessed care within 1 to 3 
years of positive test 
21 (7.2%) 21 (6.5%) 54 (14.9%) 79 (9.6%) 
Age range -Mean age 
 
32.9 years 35.5 years 36.6 years 35.9 years 
Male  
 
195 (75%) 240 (78.6%) 255 (70.4%) 586 (71.3%) 
Current PWIDs /or on opiate 
substitution at time of diagnosis 
 
174 (66.9%) 241 (79%) 302 (83.4%) 693 (84.4%) 
Genotype Tested 210 255 315  657 
 1 116 (55.2%) 117 (45.8%) 128 (40.6%) 253 (38.5%) 
2 6 (2.8%) 8 (3.1%) 16 (5%) 17 (2.5%) 
3 85 (40.4%) 126 (49.4%) 167 (53%) 383 (58.2%)  
other 3 (1.4%) 4 (1.5%) 4 (1.2%) 4 (0.6%) 
Not known 50 61   
Number started  first treatment 157 168  206 349 
Treatment  within 1 year of 
diagnosis* 
6 (3.8%) 20 (11.9%) 81 (40%) 133 (38.1%) 
Treatment from 1 to 5 year of 
diagnosis* 
23 (14.6%) 57 (33.9%) 96 (47.5%) 216 (61.6%) 
Treatment from 5 to 10 year of 
diagnosis* 
46 (29.2%) 64 (38%) 29 (14%) N/A 
Treatment after 10 years* 82 (52.2%) 
 
27 (16%) N/A N/A 
SVR 96 (61.6%)** 103 (61.3%)** 140 (67.9%) 
 
258/333 (77.4%) *** 
Complete treatment/no SVR 
data 
1 2 13 15 
Died on/after treat 0 5 2 8 
Cirrhosis when starting first 
treatment 
38 (24.2%) 45 (27.3%) 28 (13.5%) 48 (13.7%) 
Second/third 
treatment 
Commenced 26 18 17 11 
 SVR 
 
15 (57.6%)  9 (50%) 10 (58.8%) 10 (90.9%) 
Follow up Died 51  57  36  33  
Moved from area 23  47  53  58  
Lost to follow up 37  32  57  138  
 Discharged SVR 114  112  150  268  
 
*The table includes each patient from date of diagnosis; the treatment will be started at different stages in our pathways 
** The SVR data is based across genotypes and using various treatment regimens and includes individuals who were on clinical trials in our 
area  
***16 patients had not completed treatment by end of study 
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During the study 948 have commenced treatment, 872 have had one period of treatment, 68 have had 
two treatments and 8 had three. The sustained response rates of treatments have gradually improved 
throughout the study and the majority of first treatments contained interferon in the regimen. DAAs with 
interferon were included at the end of 2011. The number of individuals who started treatment within two 
years of diagnosis increased from 14.6% to 61.6%. In total 641 have obtained a SVR, 597 with a first 
treatment and 44 with second or third treatment. SVR rates are included in Table 2. In this analysis it is 
difficult to break this down by treatment genotype, duration and regimen because an individual may be 
diagnosed in one time period and have been treated at a much later stage. SVRs for first treatments are 
between 61.6 and 77.4% across the study. 
 
To further analyse the impact of different treatment pathways we have used Kaplan Meier curves (13) to 
determine whether there was a significant difference on outcomes associated with the date of first 
diagnosis and the pathways that were in place at the time of diagnosis. For all 1629 individuals who 
attended at least one appointment at the specialist service we took the date of first positive HCV test and 
analysed time to first appointment at specialist clinic, the start of first treatment and the time to SVR.   
The Kaplan-Meier survival curves for time to the 1st appointment, the 1st treatment, and SVR are shown 
in Figure 1. It shows that subgroup D (blue) has the shortest time to the 1st appointment, time to the 1st 
treatment, and time to SVR. The difference of these time periods are significantly different among the 4 
subgroups.  
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Deaths in the subgroups   
Within the study there were 570 recorded deaths, 69 of deaths were in individuals who were HCV PCR 
negative. Two hundred and eighty four died before being able to access specialist HCV care. A 
significant number in this group died from drug related deaths, HIV related illnesses or liver and 
hepatocellular carcinoma related deaths.  The majority with HIV related illness died pre 2004. Of the 196 
who died after accessing care a significant number had liver cirrhosis and liver cancer. (Table 3) 
In all groups many died from other serious illnesses not related to the liver, the main cause of death was 
heart disease (30%), lung disease (19%)  and cerebro-vascular  disease (13%) respectively. 
 
Table 3: Causes of death recorded in HCV positive individuals  
Cause of death 
Access to HCV 
care 
No access to 
HCV care 
PCR 
Negative 
Alcohol related Cirrhosis Of Liver 17 13 3 
Assault 3 3 0 
Drug related death 57 69 20 
Falling jumping or pushed from high place 0 4 0 
Drug related death/known cirrhosis 5 0 0 
HIV related death  10 58 6 
Liver cirrhosis 9 8 0 
Liver cirrhosis died from other serious illness 4 2 0 
Liver cirrhosis with liver cancer 26 14 1 
Mental and behavioural disorders due to alcohol dependence syndrome 8 5 1 
Not known 7 11 8 
Other cancer not liver related 7 14 6 
Other serious illness resulting in death 23 51 16 
Other specified viral hepatitis without mention of hepatic coma 10 14 4 
Suicide 10 18 4 
Total died 196 284 69 
Total in subgroup 1629 545 651 
% of deaths per subgroup 12.0% 52.1% 10.5% 
 
 
When the rates of death between the 4 sub-groups are viewed there is an apparent reduction in death as 
the pathways change with the most recent sub-group having the lowest death rate (Table 4). Clearly 
there are several co-founders for such an observation. 
 
Table 4: Numbers of deaths by subgroup 
Number diagnosed with Subgroup A Subgroup B Subgroup C Subgroup D 
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HCV (n=688) (n=634) (n=593) (n=1207) 
Dead before access to 
care  
181 (26.3%) 82 (12.9%) 39 (6.5%) 22 (1.8%) 
Died after access to care 
 
51 (7.4%) 57 (8.9%) 36 (6.1%) 33 (2.7%) 
Total deaths 232 (33.7%) 139 (21.9%) 75 (12.6%) 55 (4.5%) 
 
 
To investigate this further we performed a Kaplan-Meier survival curve. The number of patients in this 
analysis is 3,099 patients (23 patients with missing data for date of death or date of SVR). The starting 
point of follow-up is taken to be the date of first test. The survival time (time from the first test to all-cause 
mortality) may be exactly observed or censored at the last follow-up date (date of moving out of the 
region or 30/6/2015).The Kaplan-Meier survival curves for the 4 subgroups are shown in the figure 4.  
The length of follow up for the 4 subgroups is different. Within the same length of follow-up period (0 - 7 
years), the latest subgroup (Subgroup D) has significantly higher survival probability (i.e. lower risk of 
death) than the other 3 subgroups. We can further investigate the difference by employing Cox 
regression models (Table 5). 
This further analysis of the time to all-cause mortality, includes  potential confounding risk factors which 
are age at 1st test (continuous variable), gender (male vs. female), subgroup(A to D), HIV co-infection 
(yes or no), and SVR status (yes or no). The Cox proportional hazard model (14 ref required) is used to 
investigate whether the time to mortality are still significantly different among the 4 sub-groups after 
adjusting for age at 1st test, gender, HIV co-infection, and SVR. 
The SVR status does not satisfy the proportional hazard assumption, i.e. the baseline hazards for 
patients with & without SVR are not the same. Therefore a stratified analysis on SVR is performed to 
guarantee that the proportional hazard assumption is not violated. The results are shown in the following 
table.  
Table 5: Multivariate Cox regression analysis for the time from the first test to all-cause mortality 
Covariates Multivariate HR (95% CI) P value 
Age at the first test 1.05 (1.04 – 1.05) < 0.001 
Gender    Male vs. Female 1.28 (1.04 – 1.56) 0.018 
HIV                     Yes vs No 4.35 (3.40 – 5.56) < 0.001 
Subgroup              B vs A 0.85 (0.69 – 1.05) 0.128 
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Subgroup              C vs A 0.79 (0.61 – 1.02) 0.074 
Subgroup              D vs A 0.53 (0.40 – 0.71) < 0.001 
 
The hazard ratio of SVR is omitted since stratified Cox regression ignores the coefficient of the 
stratification factor, which is SVR in this model. We can see that after adjusting for age, gender, HIV 
infection and SVR, only the latest subgroup  (D) has significantly reduced risk of death (HR = 0.53, p < 
0.001) comparing to the earliest subgroup (A).  
Discussion 
This paper demonstrates that the referral and treatment pathway in Tayside acts as a model of best 
practice in how a co-ordinated care network can ensure widened access to testing and treatment and 
significantly improve outcomes for a cohort that contains significant numbers who are often deemed ill-
suited for hepatitis C treatment. Improving diagnosis of HCV and access to care will only be effective if 
they are able to receive effective treatment and be cured of hepatitis C. All service developments were 
aimed at achieving successful SVRs.  The greatest impact on our pathway was the introduction of 
routine dry blood spot testing (DBST) in drug services and community clinics and GP practices.  This has 
significantly contributed to an increase in the number of new hepatitis C cases. In 2008, there were 127 
new diagnosis (rate of 32.1 per 100 000 of our population) and the rate of new diagnosis increased to 
68.5 per 100 000 which is higher than the overall rate for Scotland. (15)  While the largest single change 
is the proportion of new diagnosis within the drug services, the numbers of patients diagnosed within 
general practice also continues to rise and is not diminished by the development of alternate routes into 
care.  
 
The Kaplan-Meier survival curves for time to the 1st appointment, to 1st treatment, and SVR clearly 
shows that sub-group D has the shortest time to SVR. The difference of these time periods is 
significantly different among the 4 subgroups. It is not surprising that the time to first attendance and 
commencing treatment fell, then the time to SVR also improved, but taken in the context of a much 
larger number of patients being diagnosed and referred and the number of opiate dependent patients 
with chaotic life styles, also increasing in the later subgroups, it might be expected that such patients 
would be more difficult to treat and cure. So, by opening care to all of the community affected by HCV we 
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are seeing no diminution in the markers of success of the treatment programme. Clearly in terms of total 
numbers of each subgroup the commencement of treatment and achieving SVR in this study is biased 
toward the earlier subgroups.  Patients in subgroups A, B, and C have had a much longer opportunity to 
be exposed to therapy and have also been exposed to the newer pathways of care, yet despite this bias 
against the newest pathway of care it still demonstrates it is superior. 
It is important to note that the developments in our service were not achieved by a large increase in our 
nursing and medical staff. Our service is mainly nurse led and these outcomes have been achieved by 
0.8 full time equivalent (FTE) specialist nurse when the MCN was introduced and the addition of another 
FTE nurse when DBST was introduced. The aim of the network has always been to empower colleagues 
to be involved in BBV testing and follow up and the high referral and attendance rates have been 
achieved by health care professionals such as drug workers, GPs, prison nurses and social workers 
taking the opportunity to discuss referral and treatment. Good communication and easy access to 
specialist service is important. There is a perception that individuals with hepatitis C can be “difficult to 
reach” however our centre has found that this is not the case.  We are always aware that it might be 
more likely that our services are “difficult to find” and our service redesign was aimed at providing 
services in the right time and place. 
 
The clinical database which was established in 2004 has been invaluable in tracking and following up 
patients. We have a record of every new diagnosis in our area; the data is kept prospectively and is 
updated every week. The information available is used to advise the clinical team of numbers who are 
currently in HCV service, who are lost to follow up, who have never attended a clinic or have never been 
referred, if they have died or moved out of the area. This data has been vital to showing the success of 
the redesign of our service. This data had also been used to assist with local projects carried out with 
General Practitioners and community pharmacists which have been shown to increase the numbers 
tested and accessing care.  
The most striking finding from the study has been the greater than 40% reduction in risk of death in the 
first sub group compared to the most recent. Intuitively the older age of the earlier sub-group and poorer 
HIV infection outcomes of that time would have been thought to explain this, however multi-variate 
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analysis shows this survival benefit is maintained even when SVR, HIV status and age are taken into 
account. In our cohort the dominant causes of death are drug related, trauma and suicide, all strongly 
associated with active drug use. In our final sub-group the care pathway has led to massive increase in 
testing and diagnosis of HCV infection, this would have been expected to lead to an increased risk of 
death and yet we have observed the reverse. The associated increased speed of access into care and 
focus on HCV treatment may have led to a greater degree of engagement with health services and may 
have had a stabilising effect on drug using behaviour. 
This is an observational cohort study so the power to ascribe causality between the interventions 
described and the outcomes is limited to describing associations. However it is very difficult to test the 
systems change and complex interventions undertaken here in a randomised trial, without expensive 
and large cluster randomised trials, which are probably impossible to perform.       
 
Conclusion 
In the field of HCV treatment much has been made of the waterfall of care with loss of large numbers of 
patients from the care pathway at each stage. In this study we report the outcomes of a series of 
changes to the care pathway, with modest investment in infra-structure but integration of existing 
services to work smarter. This has led to 97.5% of our HCV caseload being referred to our Specialist 
Services with 89% attending at least one clinic appointment for assessment. Over the course of the 
study with the introduction of new pathways the number who accessed specialist care within a year of 
diagnosis significantly increased from around 26.3% to 72.9%. There was a significant decrease in the 
time period from diagnosis to SVR. 
At the end of the study 78% of estimated HCV cases had been diagnosed and 40% of the total caseload 
had an SVR. Our data shows that involving colleagues within a network can significantly increase HCV 
testing, diagnosis and treatment and can bring patients who are perceived as difficult to reach into care. 
Additionally, the entry into HCV care of those traditionally thought unsuitable is associated with reduced 
risk of death.  
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